Can I Take NMN With Mounjaro? What We Know Right Now

Why there is no clear-cut yes or no from the trial data

The SURMOUNT-1 trial, published in the New England Journal of Medicine and underpinning NICE's recommendation of tirzepatide (TA1026), enrolled adults with obesity over 72 weeks and produced average weight reductions of around 20–21% at the 15 mg dose. What the trial protocol excluded, like virtually all pharmaceutical trials, was co-administration with unregulated supplements. NMN was not a listed variable. That is not a condemnation of NMN; it simply means there is no randomised controlled data on the combination, and no regulator has reviewed it. The NHS medicines page for tirzepatide lists clinically established interactions and does not mention NMN, again, because none has been studied, not because the interaction is confirmed safe.

NMN is a precursor to NAD+, a coenzyme involved in cellular energy metabolism. Proponents argue it supports mitochondrial function. These are biologically plausible ideas with a growing body of early-phase research behind them, but no large randomised trials in humans taking GLP-1 medicines have tested the theory. That gap matters when you are asking a prescriber to sign off on your full medication and supplement list.

The gastric-emptying factor: why it is worth flagging to your prescriber

Mounjaro slows gastric emptying as part of its mechanism, food moves more slowly through the stomach, which prolongs the sense of fullness and moderates blood-sugar rises after meals. This same slowdown can affect how quickly oral substances, including supplements, pass into the small intestine for absorption. The effect is most clinically significant for medicines with narrow therapeutic windows, and NMN does not fall into that category. But a reduced or delayed absorption of an oral supplement is still a real pharmacological consideration, and one that is easier to discuss in advance than to troubleshoot later.

A question our prescribers hear most weeks is some version of: I already take X, do I need to stop? The answer is almost never a blanket yes or no; it depends on what X is, what dose you are on or aiming for, and your broader health picture. NMN tends to fall into the lower-concern tier of that conversation, but flagging it is still the right move. You can read more about the eligibility and clinical-assessment process on our BMI and Mounjaro eligibility page.

What you should do before adding NMN to a Mounjaro regimen

The practical step is straightforward: list every supplement you take, including NMN, on your consultation form. This is not a bureaucratic box-tick; a prescriber reviewing a Mounjaro consultation is looking at the whole picture (medical history, current medicines, supplements) before deciding whether treatment is appropriate and at what starting dose. If you are already on Mounjaro and considering adding NMN, speak to the prescriber or aftercare team before you start, particularly if you have any underlying kidney concerns, since our page on taking Mounjaro with CKD explains how renal health factors into the prescribing decision more broadly. That conversation is short and costs nothing through a service that includes ongoing clinical support in the price.

On the cost side, it is worth noting that a single transparent private price for Mounjaro (covering the consultation, prescription and delivery) is sometimes compared unfavourably with cheaper listings online. The Mounjaro cost and price context page explains what those headline figures typically do and do not include, and why clinical oversight is the factor that matters most for a prescription medicine. Safe supply from the GPhC-registered pharmacy is verifiable; the cheapest listing online often is not.

For people exploring whether they meet the criteria for Mounjaro in the first place (perhaps because their BMI sits just below the standard threshold) our page on eligibility at BMI 27 covers the licensed criteria and the role of weight-related conditions in that assessment. The nume clinical team reviews every case individually; eligibility is never decided by an algorithm.

The bottom line on NMN and Mounjaro safety

No evidence currently suggests that NMN is dangerous alongside tirzepatide. No evidence currently confirms it is safe in that combination either, because the research has not been done. For a supplement that has not been studied with Mounjaro, the sensible position is transparent disclosure to your prescriber, not a solo decision either way. The MHRA's Yellow Card scheme exists precisely to capture unexpected effects from medicines and supplements in real-world use; if you ever notice something unexpected after starting a new supplement alongside your treatment, that is the right place to report it. Our FAQs cover a number of related questions about starting Mounjaro safely, and the consultation page is the place to check your eligibility and put your full supplement list in front of a qualified prescriber.